Covidien adds $100m CNS outfit to 'for sale' pharma arm
This article was originally published in Scrip
Mallinckrodt, the pharmaceuticals business unit of Covidien has agreed to acquire CNS Therapeutics for around $100 million. The privately held specialty pharmaceutical company is focused on developing and commercialising products for site-specific administration to the central nervous system to treat neurological disorders and intractable chronic pain.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.